{"id":40546,"date":"2023-05-22T17:31:54","date_gmt":"2023-05-22T16:31:54","guid":{"rendered":"https:\/\/www.btitrainingcenter.com\/plasma-rich-in-growth-factors-as-an-adjuvant-agent-in-non-penetrating-deep-sclerectomy\/"},"modified":"2025-07-18T11:24:27","modified_gmt":"2025-07-18T10:24:27","slug":"plasma-rich-in-growth-factors-as-an-adjuvant-agent-in-non-penetrating-deep-sclerectomy","status":"publish","type":"post","link":"https:\/\/www.btitrainingcenter.com\/fr\/plasma-rich-in-growth-factors-as-an-adjuvant-agent-in-non-penetrating-deep-sclerectomy\/","title":{"rendered":"Plasma Rich in Growth Factors as an Adjuvant Agent in Non-Penetrating Deep Sclerectomy"},"content":{"rendered":"

[vc_row content_text_aligment=”left” row_background_lines=”no”][vc_column][vc_column_text css=””]<\/p>\n

Abstract<\/h3>\n
\n
\n
\n

Background:\u00a0<\/strong>The purpose of this study is to evaluate the utility and safety of plasma rich in growth factors immunosafe eye drops (is-ePRGF) in the postoperative treatment of non-penetrating deep sclerectomy (NPDS).<\/p>\n

Methods:\u00a0<\/strong>This is a case-control study in patients with open-angle glaucoma. Group one (control) was not treated with is-ePRGF, while group two (is-ePRGF) was treated (four times a day for four months). Postoperative evaluations were performed at one day, one month, three months and six months. The main outcomes were: intraocular pressure (IOP), microcysts in blebs with AS-OCT and the number of hypotensive eye drops.<\/p>\n

Results:\u00a0<\/strong>Preoperatively, group one (n = 48 eyes) and group two (n = 47 eyes) were similar in age (71.5 \u00b1 10.7 vs. 70.9 \u00b1 10.0 years; p = 0.68), IOP (20.6 \u00b1 10.2 vs. 23.0 \u00b1 9.0 mmHg; p = 0.26) and number of hypotensive drugs (2.7 \u00b1 0.8 vs. 2.8 \u00b1 0.9; p = 0.40). The IOP at six months dropped to 15.0 \u00b1 8.0 mmHg (IOP reduction: -27.2%) and 10.9 \u00b1 4.3 mmHg (IOP reduction: -52.6%) for group one and group two, respectively (p < 0.01). At six months, blebs with microcysts were 62.5% (group one) and 76.7% (group two). Postoperative complications were observed in 12 eyes (25%) for group one and in 5 eyes (11%) for group two (p = 0.06). No specific complications related to the use of is-ePRGF were identified.<\/p>\n

Conclusions:\u00a0<\/strong>Topical is-ePRGF seems to reduce IOP and the rate of complications in the medium term after NPDS, so it can be considered as a possible safe adjuvant to achieve surgical success.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

Keywords:\u00a0<\/strong>PRGF; glaucoma filtration surgery; immunosafe eye drops; is-ePRGF; non-perforating deep sclerectomy; open-angle glaucoma; plasma rich in growth factors; surgery outcome.[\/vc_column_text][vc_empty_space][vc_column_text]<\/p>\n

Figures<\/h3>\n
\n

[\/vc_column_text][vc_empty_space][\/vc_column][\/vc_row][vc_row content_placement=”middle” content_text_aligment=”center”][vc_column]

\n\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\n<\/div>[vc_empty_space height=”50px”][\/vc_column][\/vc_row][vc_row][vc_column]\n T\u00e9l\u00e9charger l'article<\/span>\n <\/a>[\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

J Clin Med. 2023 May 22;12(10):3604.<\/strong>
\nThe purpose of this study is to evaluate the utility and safety of plasma rich in growth factors immunosafe eye drops (is-ePRGF) in the postoperative treatment of non-penetrating deep sclerectomy (NPDS).<\/p>\n","protected":false},"author":2002,"featured_media":40504,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[155],"tags":[],"class_list":["post-40546","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medecine-regenerative"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/posts\/40546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/users\/2002"}],"replies":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/comments?post=40546"}],"version-history":[{"count":2,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/posts\/40546\/revisions"}],"predecessor-version":[{"id":40548,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/posts\/40546\/revisions\/40548"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/media\/40504"}],"wp:attachment":[{"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/media?parent=40546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/categories?post=40546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/tags?post=40546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}